CD274 and non-small cell lung carcinoma: Currently, platinum-based chemotherapy (typically carboplatin or cisplatin plus pemetrexed) combined with immunotherapy is the standard treatment for advanced NSCLC patients who are ineligible for approved molecular targeted therapies, regardless of histology and PD-L1 expression levels.